Summary There is a need for safe and effective platform vaccines to protect against COVID and other infectious diseases In this randomized double blinded placebo controlled Phase trial we evaluate the safety and efficacy of multi dose Bacillus Calmette Guerin BCG vaccine for prevention of COVID and other infectious disease in a COVID unvaccinated at risk community based cohort The at risk population are adults with type diabetes We enrolled subjects and randomized to BCG and to placebo There were no drop outs over the month trial A cumulative incidence of of placebo treated and of BCG treated participants meets criteria for confirmed COVID yielding an efficacy of The BCG group also displays fewer infectious disease symptoms and lesser severity and fewer infectious disease events per patient including COVID There were no BCG related systemic adverse events BCG s broad based infection protection suggests that it may provide platform protection against new SARS CoV variants and other pathogens Sources 